Use of proton pump inhibitors correlates with increased risk of pancreatic cancer: A case-control study in Taiwan

Kuwait Medical Journal

Volumn 46, Issue 1, 2014, Pages 44-48

  Lai, Shih Wei ^a,b   Sung, Fung Chang ^b,c   Lin, Cheng Li ^b,c   Liao, Kuan Fu ^c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Pancreatic cancer; Proton pump inhibitor

Indexed keywords

EID: 84894598580     PISSN: 00235776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. IntJ Cancer 2010; 127:2893-2917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
3. Department of Health. Taiwan: Main Causes of Death in 2011. http://www.doh.gov.tw. [cited in 2013 March].
4. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-1437.
5. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301:2553-2562.
6. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-1617.
7. Bao Y, Spiegelman D, Li R, Giovannucci E, Fuchs CS, Michaud DS. History of peptic ulcer disease and pancreatic cancer risk in men. Gastroenterology 2010; 138:541-549.
8. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161-167.
9. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001; 33:32-35.
10. Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115:275-280.
11. Garcia Rodriguez LA, LagergrenJ, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006; 55:1538-1544.
12. Chao C, Hellmich MR. Gastrin, inflammation, and carcinogenesis. Curr Opin Endocrinol Diabetes Obes 2010; 17:33-39.
13. Smith JP, Liu G, Soundararajan V, McLaughlin PJ and Zagon IS. Identification and characterization of CCK-B/ gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 1994; 266:R277-283.
14. Smith JP, Fantaskey AP, Liu G, Zagon IS. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 1995; 268:R135-141.
15. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore) 2010; 89:295-299.
16. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011; 106:1697-1704.
17. Liao KF, Lai SW, Li Cl, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012; 27:709-713.
18. Bradley MC, Murray LJ, Cantwell MM, Hughes CM. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer 2012; 106:233-239.
19. Parsa I, Marsh WH, Sutton AL. An in vitro model of human pancreas carcinogenesis: effects of nitroso compounds. Cancer 1981; 47:1543-1551.